Special Issue

The Prevention and Treatment of Prostate Cancer

Message from the Guest Editors

Advances in prostate cancer treatment have focused on improving precision medicine, immunotherapy, and new drug developments, such as PARP inhibitors, radiopharmaceuticals, and next-generation antiandrogens. These advancements reflect a trend toward more personalized, targeted, and effective treatments for prostate cancer, improving both survival rates and quality of life for patients. We are pleased to invite you to contribute to this Special Issue of Cancers titled "The Prevention and Treatment of Prostate Cancer". This Special Issue will promote studies exploring the mechanisms controlling prostate cancer initiation and progression to open new avenues for identifying novel therapeutic targets in fighting this deadly disease. In this Special Issue, original research articles and reviews are welcome. Research areas may include: Prostate cancer prevention research on genetic/epigenetic risk factors. lifestyle/diet, chemoprevention, chronic inflammation, infections, and microbiome; Mechanisms controlling prostate cancer tumorigenicity and metastasis; Innovative methods to investigate prostate cancer progression Advances in prostate cancer precision medicine

Guest Editors

Dr. Ning Wang

- 1. Leicester Cancer Research Centre, University of Leicester, Leicester, UK
- 2. Division of Clinical Medicine, University of Sheffield, Sheffield, UK

Dr. Kirsty Hodgson

Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK

Deadline for manuscript submissions

closed (31 March 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/207473

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

